In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-readyIn this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready

Transforming Pediatric Rare Disease Trials Through Modeling and Simulation, and Site Networks, Upcoming Webinar Hosted by Xtalks

2026/01/29 22:15
3 min read

In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready pediatric dose selection with fewer patients. Attendees will learn why pediatric rare disease trials require adapted clinical operations including, optimized sampling, flexible protocols and caregiver-centric execution, to remain feasible and efficient. The featured speakers will discuss how pediatric site networks operationalize model-informed designs by accelerating start-up, improving recruitment and ensuring consistent, high-quality execution across specialized centers.

TORONTO, Jan. 29, 2026 /PRNewswire/ — Drug developers face unique challenges in pediatric rare disease trials, including small and geographically dispersed patient populations, strict ethical limits on sampling and sparse early clinical data. In a competitive landscape where speed is critical and every month can influence funding rounds and regulatory milestones, traditional development approaches often fall short. However, forward-thinking strategies are transforming these challenges into opportunities to accelerate approval and market entry.

This webinar explores how expertise in modeling and simulation is reshaping pediatric trial design by simulating drug pharmacokinetics across age groups, growth phases and disease states. Approaches such as population pharmacokinetic (PK) modeling, allometric scaling, adult extrapolation and clinical trial simulation enable more accurate exposure-response predictions, optimize sparse sampling strategies to meet FDA expectations and leverage early PK/PD data. In appropriate pediatric-specific scenarios, these tools can support direct-to-patient development strategies, reducing reliance on redundant healthy volunteer studies, shortening timelines and minimizing burden on children and families.

Beyond study design, pediatric rare disease trials frequently encounter operational challenges, including delayed site start-ups, recruitment shortfalls, caregiver burden and protocol misalignment, which can lead to screening failures and increased costs. Pediatric site networks play a critical role in addressing these barriers by connecting specialized centers, standardizing processes and sharing rare-disease expertise through key opinion leader (KOL) collaboration.

Drawing on real-world examples and cross-functional perspectives that integrate modeling, clinical operations and site networks, this webinar presents proven strategies to de-risk development programs, bridge adult-to-pediatric data gaps and enable more efficient, ethical and feasible pediatric rare disease trials. Attendees will learn how to move from early data generation to successful site-level execution without compromising patient safety or scientific rigor.

Register for this webinar to learn how pediatric rare disease trials can be strengthened through model-informed study design and site network execution.

Join J. Stuart Elborn CBE, MD, FMedSci, Honorary Professor of Medicine, Queens University Belfast; Deputy Chair, Regulatory and Quality Improvement Authority; Maria-Cruz Morillo, Allucent Center of Expertise, Rare Diseases, Allucent; and Jessica K. Roberts, PhD, MSCI, MBA, Senior Director, Pharmacometrics, Allucent, for the live webinar on Wednesday, February 18, 2026, at 11am EST (5pm CET/EU-Central).

For more information, or to register for this event, visit Transforming Pediatric Rare Disease Trials Through Modeling and Simulation, and Site Networks.

ABOUT XTALKS

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transforming-pediatric-rare-disease-trials-through-modeling-and-simulation-and-site-networks-upcoming-webinar-hosted-by-xtalks-302672561.html

SOURCE Xtalks

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

The post Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference appeared on BitcoinEthereumNews.com. Key Takeaways Ethereum’s new roadmap was presented by Vitalik Buterin at the Japan Dev Conference. Short-term priorities include Layer 1 scaling and raising gas limits to enhance transaction throughput. Vitalik Buterin presented Ethereum’s development roadmap at the Japan Dev Conference today, outlining the blockchain platform’s priorities across multiple timeframes. The short-term goals focus on scaling solutions and increasing Layer 1 gas limits to improve transaction capacity. Mid-term objectives target enhanced cross-Layer 2 interoperability and faster network responsiveness to create a more seamless user experience across different scaling solutions. The long-term vision emphasizes building a secure, simple, quantum-resistant, and formally verified minimalist Ethereum network. This approach aims to future-proof the platform against emerging technological threats while maintaining its core functionality. The roadmap presentation comes as Ethereum continues to compete with other blockchain platforms for market share in the smart contract and decentralized application space. Source: https://cryptobriefing.com/ethereum-roadmap-scaling-interoperability-security-japan/
Share
BitcoinEthereumNews2025/09/18 00:25
Microsoft Corp. $MSFT blue box area offers a buying opportunity

Microsoft Corp. $MSFT blue box area offers a buying opportunity

The post Microsoft Corp. $MSFT blue box area offers a buying opportunity appeared on BitcoinEthereumNews.com. In today’s article, we’ll examine the recent performance of Microsoft Corp. ($MSFT) through the lens of Elliott Wave Theory. We’ll review how the rally from the April 07, 2025 low unfolded as a 5-wave impulse followed by a 3-swing correction (ABC) and discuss our forecast for the next move. Let’s dive into the structure and expectations for this stock. Five wave impulse structure + ABC + WXY correction $MSFT 8H Elliott Wave chart 9.04.2025 In the 8-hour Elliott Wave count from Sep 04, 2025, we saw that $MSFT completed a 5-wave impulsive cycle at red III. As expected, this initial wave prompted a pullback. We anticipated this pullback to unfold in 3 swings and find buyers in the equal legs area between $497.02 and $471.06 This setup aligns with a typical Elliott Wave correction pattern (ABC), in which the market pauses briefly before resuming its primary trend. $MSFT 8H Elliott Wave chart 7.14.2025 The update, 10 days later, shows the stock finding support from the equal legs area as predicted allowing traders to get risk free. The stock is expected to bounce towards 525 – 532 before deciding if the bounce is a connector or the next leg higher. A break into new ATHs will confirm the latter and can see it trade higher towards 570 – 593 area. Until then, traders should get risk free and protect their capital in case of a WXY double correction. Conclusion In conclusion, our Elliott Wave analysis of Microsoft Corp. ($MSFT) suggested that it remains supported against April 07, 2025 lows and bounce from the blue box area. In the meantime, keep an eye out for any corrective pullbacks that may offer entry opportunities. By applying Elliott Wave Theory, traders can better anticipate the structure of upcoming moves and enhance risk management in volatile markets. Source: https://www.fxstreet.com/news/microsoft-corp-msft-blue-box-area-offers-a-buying-opportunity-202509171323
Share
BitcoinEthereumNews2025/09/18 03:50
SHIB Price Analysis for February 8

SHIB Price Analysis for February 8

The post SHIB Price Analysis for February 8 appeared on BitcoinEthereumNews.com. Original U.Today article Can traders expect SHIB to test the $0.0000070 range soon
Share
BitcoinEthereumNews2026/02/09 00:26